Re­im­burse­ment be­gins slow­ly for Bio­gen’s ex­pen­sive Alzheimer’s drug

Medicare Ad­min­is­tra­tive Con­trac­tors, or MACs, are now spo­rad­i­cal­ly re­im­burs­ing for Bio­gen’s ex­pen­sive new Alzheimer’s drug in lim­it­ed pock­ets across the US, as CMS has sev­er­al months left to fin­ish its de­ci­sion on na­tion­al cov­er­age.

The slow trick­le of MAC cov­er­age, which one se­nior Bio­gen em­ploy­ee told End­points News is “re­gion­al at best,” comes as there’s been “no uptick in us­age thus far,” con­tin­u­ing the slow roll­out fol­low­ing FDA’s ac­cel­er­at­ed ap­proval in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER